Saniona reported Q4 2025 revenue of SEK 4.6 million (down 98.5% YoY), operating loss of SEK 46.5 million and net loss attributable to shareholders of SEK 41.7 million, with basic and diluted EPS at SEK -0.30. Cash and cash equivalents totaled SEK 580.8 million at December 31, 2025. For FY 2025, revenue was SEK 434.4 million (up 29.8% YoY), operating profit was SEK 271.0 million (up 12.0% YoY) and net profit attributable to shareholders was SEK 284.6 million (up 50.8% YoY), with basic EPS of SEK 2.21 and diluted EPS of SEK 2.15. Business highlights included leadership appointments announced on December 17 across clinical development, translational medicine, toxicology and CMC. In its CEO commentary, Saniona said 2025 was a “transformational year,” citing licensing deals with Jazz Pharmaceuticals for SAN2355 and Acadia for SAN711/ACP-711 that generated USD 70.5 million in upfront payments and potential eligibility for about USD 1.6 billion in milestones plus royalties. Jazz is preparing first-in-human studies for SAN2355, with a USD 7.5 million milestone triggered upon Phase 1 initiation, while Acadia plans to initiate a Phase 2 essential tremor study in 2026, triggering a USD 10 million milestone. Saniona also reiterated plans to advance proprietary programs SAN2668, SAN2465 and SAN2219 toward the clinic, targeting two Phase 1 study starts in 2026 and a third in early 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Saniona AB published the original content used to generate this news brief on February 26, 2026, and is solely responsible for the information contained therein.
Comments